Prognostic value of 18F-FDG PET/CT in patients with soft tissue sarcoma: comparisons between metabolic parameters
Prognostic value of 18F-FDG PET/CT in patients with soft tissue sarcoma: comparisons between metabolic parameters
复制标题
DOI：
10.1007/s00256-014-1832-7
复制
发表时间：
2014-05-01
影响因子：
2.1
通讯作者：
Choi, Joon Young
中科院分区：
文献类型：
--
作者：
Hong, Sun-pyo;Lee, Seung Eun;Choi, Joon Young
目的探讨软组织肉瘤（STS）患者PET体积参数与预后的关系。我们回顾性分析了55例经病理证实的STS患者，他们接受了（18）f -氟脱氧葡萄糖（F-18-FDG） PET/CT预处理。测定原发肿瘤的最大标准化摄取值（SUVmax）、平均SUV （SUVavg）、代谢肿瘤体积（MTV）和病变总糖酵解（TLG），以阈值SUV作为肝活性，确定肿瘤边界。根据代谢参数和其他临床变量对总生存率进行单因素和多因素生存分析。在随访期间（29 +/- 23个月），55例患者中有19例（35%）发生癌症相关死亡。在单因素分析中，AJCC分期（IV期vs I-III期，风险比(HR) = 2.837, p = 0.028）、坏死（G2期vs g1期，HR = 3.890, p = 0.004）、SUVmax（增加1个单位，HR = 1.146, p = 0.008）、SUVavg（增加1个单位，HR = 1.469, p = 0.032）和治疗方式（非手术治疗vs手术治疗，HR = 4.467, p = 0.002）是总生存率的显著预测因子。在多因素分析中，SUVmax （HR = 1.274, p = 0.015）、治疗方式（HR = 3.353, p = 0.019）和坏死（HR = 5.985, p = 0.006）被确定为与总生存率降低相关的重要独立预后因素。原发肿瘤的SUVmax是STS患者总生存的一个重要的独立代谢预后因素。基于容积的PET参数可能无法添加SUVmax以外的预后信息。
Objectives To investigate the relationship between volume-based PET parameters and prognosis in patients with soft tissue sarcoma (STS).We retrospectively reviewed 55 patients with pathologically proven STS who underwent pretreatment with (18) F-Fluorodeoxyglucose (F-18-FDG) PET/CT. The maximum standardized uptake value (SUVmax), average SUV (SUVavg), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of primary tumors were measured using a threshold SUV as liver activity for determining the boundary of tumors. Univariate and multivariate survival analyses for overall survival were performed according to the metabolic parameters and other clinical variables.Cancer-related death occurred in 19 of 55 patients (35 %) during the follow-up period (29 +/- 23 months). On univariate analysis, AJCC stage (stage IV vs. I-III, hazard ratio (HR) = 2.837, p = 0.028), necrosis (G2 vs. G0-G1, HR = 3.890, p = 0.004), SUVmax (1 unit - increase, HR = 1.146, p = 0.008), SUVavg (1 unit - increase, HR = 1.469, p = 0.032) and treatment modality (non-surgical therapy vs. surgery, HR = 4.467, p = 0.002) were significant predictors for overall survival. On multivariate analyses, SUVmax (HR = 1.274, p = 0.015), treatment modality (HR = 3.353, p = 0.019) and necrosis (HR = 5.985, p = 0.006) were identified as significant independent prognostic factors associated with decreased overall survival.The SUVmax of the primary tumor is a significant independent metabolic prognostic factor for overall survival in patients with STS. Volume-based PET parameters may not add prognostic information outside of the SUVmax.